<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004814</url>
  </required_header>
  <id_info>
    <org_study_id>199/12023</org_study_id>
    <secondary_id>UMB-55901</secondary_id>
    <nct_id>NCT00004814</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic&#xD;
      polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by&#xD;
      participating institution.&#xD;
&#xD;
      One group receives copolymer 1, a mixture of synthetic polypeptides composed of 4 amino&#xD;
      acids, subcutaneously each day for 2 years.&#xD;
&#xD;
      The other group receives an injection of placebo daily for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1991</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>250</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>copolymer 1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Clinically or laboratory-supported definite multiple sclerosis&#xD;
&#xD;
          -  Neurologically stable for at least 30 days prior to entry Expanded Disability Status&#xD;
             Scale score no greater than 5&#xD;
&#xD;
          -  At least 2 documented relapses within 2 years prior to entry Onset of first relapse at&#xD;
             least 1 year prior to randomization&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Biologic therapy: No prior copolymer 1&#xD;
&#xD;
          -  Immunosuppressive therapy: No prior cytotoxic immunosuppressives, i.e.: Azathioprine&#xD;
             Cyclophosphamide Cyclosporine At least 30 days since corticosteroids&#xD;
&#xD;
          -  Radiotherapy: No prior lymphoid irradiation&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Not HIV or HTLV-I seropositive No insulin-dependent diabetes mellitus No Lyme disease&#xD;
             No requirement for aspirin or chronic nonsteroidal anti-inflammatory drugs No pregnant&#xD;
             or nursing women Adequate contraception required of fertile women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth P. Johnson</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <verification_date>January 1997</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>multiple sclerosis</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

